The International Society for Heart and Lung Transplantation has reported that 34,102 adult lung transplantations were performed worldwide from 1995 to 2011. The most common reason for lung transplantation was chronic obstructive pulmonary disease (34%), followed by idiopathic pulmonary fibrosis (23%), and cystic fibrosis (17%). The overall median survival was 5.5 years, with 1- and 5-year survival rates of 79 and 53%, respectively, following lung transplantation, and 63 and 44%, respectively, following heart-lung transplantation [
1]. Because the number of lung transplant survivors has increased, the need for surgical intervention for non-pulmonary conditions, such as peptic ulcer perforation, cholecystitis, and necrotising colitis, has also increased. These non-pulmonary conditions are caused by underlying diseases, post-transplant immunosuppressive treatment regimens, and the transplant procedure itself [
2]. Safe and effective management of general anesthesia for surgical intervention in these patients requires consideration of the physiology of the transplanted lung and the effect of immunosuppressant agents. We describe here the management of two patients who underwent non-transplant surgery under general anesthesia following lung transplantation.
Discussion
Lung transplantation has become a reliable option for treatment of end-stage respiratory disease in recent years, with improved outcomes credited to aggressive perioperative care. However, lung transplantation survivors still face high morbidity and mortality and usually need continuous medical treatment throughout their lives. The most common causes of death are graft failure and non-cytomegalovirus infection within the first year, and bronchiolitis obliterans syndrome and non-cytomegalovirus infection after the first year. The risk factors for complications within the first year include the patient's underlying lung disease, acute rejection, and infection. The risk factors after 1 year are similar, but may also include immunosuppressive therapy. Immunosuppression can be divided into induction and maintenance therapy, with agents used similar following lung and heart-lung transplantation. Induction agents include interleukin-2 receptor antagonist, alemtuzumab, anti-thymocyte globulin and anti-lymphocyte globulin, but the use of induction therapy is decreasing. Maintenance therapy consists of combination regimens, with the most frequently commonly used being tacrolimus- and cyclosporine-based regimens. The optimal regimens include tacrolimus plus either mycophenolate mofetil or azathioprine. Immunosuppressive agents, however, contribute to the development of diabetes, hypertension, renal dysfunction, osteoporosis, and malignancy. Hypertension and diabetes have been shown to develop in 82.9 and 40.5% of patients, respectively within 5 years of lung transplantation [
1,
2,
3].
Although the incidence of patients requiring surgical intervention after lung transplantation has not been determined, it is generally higher than for non-transplant patients. These findings are similar to those observed following the transplantation of other organs, with post-transplantation complications resulting from patients' immunocompromised status, their underlying diseases, and the transplantation procedure itself. For example, the incidence of major non-pulmonary surgical procedures in lung transplant recipients was found to be 17.7% [
2]. The mortality rate during the first month after lung transplantation was 50%, but only 9.1% after 1 month. Emergency operations were associated with a 35.7% mortality rate, compared with 0% for elective operations. The incidence of abdominal processes among lung transplant recipients was reported to be 21%, with bowel obstruction being the most common cause, followed by peptic ulcer and cholestasis [
4].
It is important to determine a patient's general status, medications, and transplanted lung physiology before general anesthesia. Pulmonary function tests, exercise tests, and re-hospitalization can be helpful in evaluating the functional status of the patient after lung transplantation. Medications, including immunosuppressants, antihypertensives, and diuretics, should be continued up to the day of surgery and restarted as soon as possible following surgery [
3,
5].
The physiology of the transplanted lung should also be considered when selecting ventilator modes and parameters for general anesthesia. During the first month after transplantation, the total vital capacity and the first second forced expiratory volume usually decrease, thereafter increasing gradually, while PaCO
2 values tend to normalize within 15 days. Lung denervation during transplantation has minimal effect on airway tone and hypoxic pulmonary vasoconstriction. As lymphatic drainage is interrupted during trachea and bronchial resection, the transplanted lung is highly susceptible to volume overload; therefore, extreme caution must be exercised to avoid fluid overloading and pulmonary edema [
3,
6,
7,
8].
Barotrauma is another important factor to consider during general anesthesia in the transplanted lung. In double lung transplantation, consideration of ventilation management to avoid one-sided lung hyperinflation is not needed. However, in single lung transplantation, the compliance of the native lung differs from that of the transplanted lung, with ventilator flow directed towards the more compliant lung. Emphysema patients who receive a single lung transplant may develop over distension of the native lung; pulmonary fibrosis patients who receive a single lung may experience over distension of the transplanted lung. Two ventilator machines may be required, one for each lung, in patients with a single transplanted lung who also have a diseased native lung. Hyperinflation of one lung can result in mediastinal shifting and pneumothorax. To protect the less compliant lung, a low tidal volume of less than 7 ml/ideal body weight, pressure control mode, PEEP, and a high respiratory rate are recommended. Tidal volume should be reduced to avoid hypocapnia, especially during single lung ventilation. Limiting PIP to 30-35 cmH
2O and plateau pressure to 20-25 cmH
2O is recommended to avoid barotrauma at the anastomosis site and alveoli (
Table 1). A PEEP of 5-8 cmH
2O is indicated for patients who undergo double lung transplantation [
3,
9,
10].
Although propofol, thiopental sodium, and etomidate can be used to induce anesthesia, etomidate is preferred when there is a risk of hemodynamic instability. TCI with propofol plus remifentanil, or a volatile agent plus remifentanil, is suitable for maintaining anesthesia. Cisatracurium, rocuronium, vecuronium, and mivacurium are all suitable for neuromuscular blockade, but the recovery time and amount should be considered [
11]. Care should be taken with tracheal intubation in double lung transplant recipients because of possible injury to the anastomosis site. Since bronchodilators are not effective with repeated graft rejection, deep anesthesia should be maintained to avoid bronchospasm due to airway hyper-reactivity [
12].
For our two patients, we used different kinds of neuromuscular blocks, anesthetic induction agents, and maintenance methods. Neuromuscular blockers such as rocuronium and cisatracurium were suitable for muscle relaxation, and induction agents such as propofol and etomidate induced rapid loss of consciousness without hemodynamic instability. Both maintenance methods, propofol plus remifentanil and sevoflurane plus remifentanil, provided suitable hemodynamic stability. As both our patients had undergone double lung transplantation, we used a single lumen tube and a single ventilator machine for abdominal surgery. We used a pressure control mode to protect the graft and maintain low tidal volumes of less than 7 ml/kg with PIP less than 30 cmH
2O. Since the tracheal anastomosis site may be injured in double lung transplant recipients, caution is needed when performing endotracheal intubation. Fiberoptic bronchoscope, videoscope, and optiscope are helpful in examining the anastomosis site while intubating. Since the anastomosis sites of the trachea were intact in both our patients, intubation was not problematic. In patients who undergo single lung transplantation, two ventilator machines would be used via a double lumen tube to isolate the native and engrafted lungs. In Patient 1, we inserted arterial and central venous catheters to monitor hemodynamic changes due to the emergency nature of the surgery; however, in general, invasive procedures should be minimized to avoid infection. Also, fluid was infused cautiously to avoid pleural effusion, with inotropic agents chosen to elevate the mean arterial pressure. Central venous pressure and stroke volume variation were monitored to assess volume status. Stroke volume variation is reportedly affected by the depth of tidal volume, with this variation lower in patients with low tidal volume [
13]. Even when tidal volume is lower, measuring stroke volume variation from the beginning of the operation can predict intravascular volume status compared with baseline. Awareness of this limitation is important, as is follow up of the accuracy of dynamic indices. This patient's postoperative respiratory failure was considered to result from the inappropriate recovery of spontaneous respiration and laryngeal edema. He recovered after prolonged mechanical ventilation and dexamethasone injection. We did not administer intraoperative steroid injections to either patient due to the short operating time and their routine treatment with steroids, but additional steroids may be necessary during long and stressful procedures.
As the number of patients undergoing lung transplantation increases, so will those who require general anesthesia for non-pulmonary surgery. A review of each patient's general status and medications, as well as an awareness of any complications developing after transplantation, must be considered. Intraoperative ventilator settings should depend on whether a patient has received a single or double lung transplantation, and a strict perioperative aseptic technique of postoperative lung care is required to recover normal lung function. Measures to protect the transplanted lung include a pressure control mode ventilator with PEEP, a low tidal volume of less than 7 ml/kg with PIP less than 30 cmH2O, single lumen ventilation in double lung transplant recipients and double lumen ventilation with two ventilators in single lung transplant recipients, and minimal fluid therapy.